Sort
15,440 grants matching “organoids”
Making cancer precision medicine real: bottlenecks and opportunities
$972,460Todd R. Golub · Broad Institute, Inc. · R35 · FY2024 · CA
University of Michigan Center for Gastrointestinal Research
$972,429Chung Owyang · University Of Michigan At Ann Arbor · P30 · FY2017 · DK
Gastroesophageal junction stem cells as the origin of Barretts esophagus and cancer
$972,000Timothy Cragin Wang · Columbia University Health Sciences · R01 · FY2022 · CA
"A Novel Role for the UPR Component, ATF6 in AD-associated Neuroprotective Pathways"
$971,032Randal J. Kaufman · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2021 · AG
Precancer Atlas of Familial Adenomatous Polyposis
$970,941Michael P Snyder · Stanford University · U2C · FY2023 · CA
Pittsburgh Center for Kidney Research
$969,843Thomas R. Kleyman · University Of Pittsburgh At Pittsburgh · U54 · FY2023 · DK
Identification of Cooperative Genetic Alterations in the Pathogenesis of Oral Cancer
$969,709John B Sunwoo · Stanford University · U01 · FY2015 · DE
Program to promote lung regeneration and block fibrosis
$968,976Harold A Chapman · University Of California, San Francisco · R35 · FY2021 · HL
Program to promote lung regeneration and block fibrosis
$968,766Harold A Chapman · University Of California, San Francisco · R35 · FY2022 · HL
Program to promote lung regeneration and block fibrosis
$968,766Harold A Chapman · University Of California, San Francisco · R35 · FY2023 · HL
Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development
$967,715John David O'Neill · Xylyx Bio, Inc. · R44 · FY2025 · DK
Biological Analysis Core
$967,665Hemali Phatnani · Columbia University Health Sciences · U54 · FY2024 · AG
Identifying and targeting collateral lethal vulnerabilities in cancers
$967,038Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · U01 · FY2025 · CA
Identifying and targeting collateral lethal vulnerabilities in cancers
$967,038Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · U01 · FY2023 · CA
Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug development
$966,420John David O'Neill · Xylyx Bio, Inc. · R44 · FY2025 · CA
Program to promote lung regeneration and block fibrosis
$966,372Harold A Chapman · University Of California, San Francisco · R35 · FY2025 · HL
Tracking the evolution of breast cancer through single cell analyses of premalignant breast tissues from women at high risk for cancer development
$966,150Joan Siefert Brugge · Harvard Medical School · R35 · FY2024 · CA
Targeting Epigenetic Circuits in B-Cell Lymphomas
$965,684Ari M. Melnick · Weill Medical Coll Of Cornell Univ · R35 · FY2024 · CA
Personalized Cystic Fibrosis Therapy and Research Center
$965,562Anjaparavanda P Naren · Cincinnati Childrens Hosp Med Ctr · P30 · FY2023 · DK
Program to promote lung regeneration and block fibrosis
$965,500Harold A Chapman · University Of California, San Francisco · R35 · FY2020 · HL
Extracellular vesicles in Environmental Epidemiology Studies of Aging
$965,146Andrea Baccarelli · Columbia University Health Sciences · R35 · FY2022 · ES
Unlocking the postnatal human brain using activity augmented organoids
$964,746Christopher Donald Makinson · Columbia University Health Sciences · DP2 · FY2025 · MH
University of Michigan Center for Gastrointestinal Research
$964,011Chung Owyang · University Of Michigan At Ann Arbor · P30 · FY2019 · DK
Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer models
$963,693William C Hahn · Dana-Farber Cancer Inst · U01 · FY2022 · CA
Peripheral Nerve-on-a-chip for Predictive Preclinical Pharmaceutical Testing
$963,541Jabe L Curley · Axosim, Inc. · R42 · FY2017 · TR